Oritavancin Diphosphate

奥利万星磷酸盐

Report date: 2025/01/07 09:55:38
NMEQIDP

Base Information

Drug NameOritavancin Diphosphate
Drug Alias Name奥利万星二磷酸Oritavancine奥他凡星Oritavancinum奥古霉素 +[15] 
ClassificationSmall molecules > Synthetic peptideSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionCell wall inhibitorsPeptidoglycan inhibitors
TargetsPeptidoglycan
Therapy Area/IndicationsAcute bacterial skin and skin structure infectionsWounds and InjuriesInflammation +[10] 
Global Approved IndicationsAcute bacterial skin and skin structure infectionsSkin Diseases, Bacterial
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/08/06
Country/TerritoryBulgariaUnited StatesUkraine +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesMelinta TherapeuticsXediton Pharmaceuticals IncMelinta Therapeutics LLC +[8] 
Inactive CompaniesTarganta Therapeutics Co
Active IndicationsAcute bacterial skin and skin structure infectionsSkin Diseases, BacterialGram-Positive Bacterial Infections
Inactive IndicationsWounds and InjuriesInflammationWound Infection +[7] 

Other Information

ATC CodeJ01XA05
Related LinksWikipediaDrugBankKEGG